Accelerating therapeutic antibody discovery with precision and scalability

Accelerating therapeutic antibody discovery with precision and scalability

Accelerating therapeutic antibody discovery with precision and scalability

Yeast Display Antibody Discovery

At DuneX Biosciences, we specialize in yeast display–based antibody discovery and engineering, providing end-to-end solutions for biotech and pharmaceutical partners. Our advanced FACS-based selection platform enables rapid identification, affinity maturation, and validation of high-performing antibody candidates — reducing timelines and boosting discovery success rates.

Workflow Overview

Our streamlined yeast display discovery workflow integrates advanced automation, data analytics, and high-throughput screening to deliver validated antibody candidates rapidly and efficiently.

Package Pricing

Discovery Starter

$18,000

1 library (10⁷ diversity), 2 rounds FACS selection, binding validation by flow or ELISA.

6 weeks TAT

Affinity Optimization

$25,000

Affinity maturation with 3 additional sorting rounds and BLI kinetic analysis for top clones.

8 weeks TAT

Full Campaign (End-to-End)

$45,000

Custom library (10⁹ diversity) + up to 5 rounds FACS selection + NGS analysis + recombinant expression & purification deliverables.

10 weeks TAT

Turnaround: 6–10 weeks per complete discovery campaign

Deliverables: Top antibody sequences + binding data + enriched yeast clones

Applications: Therapeutic antibodies • Bispecifics • Dianostic reagents • Target validation

Core Services

Custom Library Construction

$8,000

Design and generate scFv or Fab libraries (immune, semi-synthetic, or naïve, 10⁷–10⁹ diversity).

FACS-Based Binder Selection

$5,000/round

Multi-round enrichment on target antigens using Sony SH800 / BD FACSAria; gating based on antigen-binding fluorescence.

Affinity Maturation

$6,000

Directed evolution through chain shuffling or error-prone PCR to enhance affinity and specificity.

Epitope Binning & Kinetic Screening

$3,500

BLI / SPR analysis to rank clones by binding kinetics and epitope diversity.

Sequencing & Bioinformatics

$2,000

NGS-based repertoire profiling, clone clustering, and sequence optimization report.

Recombinant Expression & Purification

$2,500

Small-scale antibody expression (E. coli / mammalian) and purification for validation assays.

FAQ

1. What is yeast surface display and why is it widely used for antibody discovery?
1. What is yeast surface display and why is it widely used for antibody discovery?
1. What is yeast surface display and why is it widely used for antibody discovery?
1. What is yeast surface display and why is it widely used for antibody discovery?
2. What types of libraries can be constructed for yeast display?
2. What types of libraries can be constructed for yeast display?
2. What types of libraries can be constructed for yeast display?
2. What types of libraries can be constructed for yeast display?
3. What is the typical library size achievable?
3. What is the typical library size achievable?
3. What is the typical library size achievable?
3. What is the typical library size achievable?
4. What antibody formats can be displayed?
4. What antibody formats can be displayed?
4. What antibody formats can be displayed?
4. What antibody formats can be displayed?
5. How does FACS-based selection improve binder quality?
5. How does FACS-based selection improve binder quality?
5. How does FACS-based selection improve binder quality?
5. How does FACS-based selection improve binder quality?
6. How many rounds of selection are typically required?
6. How many rounds of selection are typically required?
6. How many rounds of selection are typically required?
6. How many rounds of selection are typically required?
7. What is the minimal antigen quantity required?
7. What is the minimal antigen quantity required?
7. What is the minimal antigen quantity required?
7. What is the minimal antigen quantity required?
8. Can yeast display identify high-affinity and high-specificity variants?
8. Can yeast display identify high-affinity and high-specificity variants?
8. Can yeast display identify high-affinity and high-specificity variants?
8. Can yeast display identify high-affinity and high-specificity variants?
9. Do you support affinity maturation of existing antibodies?
9. Do you support affinity maturation of existing antibodies?
9. Do you support affinity maturation of existing antibodies?
9. Do you support affinity maturation of existing antibodies?
10. How do you confirm affinity improvements?
10. How do you confirm affinity improvements?
10. How do you confirm affinity improvements?
10. How do you confirm affinity improvements?
11. What QC steps are included during library construction?
11. What QC steps are included during library construction?
11. What QC steps are included during library construction?
11. What QC steps are included during library construction?
12. Can you work with membrane proteins or multi-pass GPCR targets?
12. Can you work with membrane proteins or multi-pass GPCR targets?
12. Can you work with membrane proteins or multi-pass GPCR targets?
12. Can you work with membrane proteins or multi-pass GPCR targets?
13. How do you ensure correct protein folding on the yeast surface?
13. How do you ensure correct protein folding on the yeast surface?
13. How do you ensure correct protein folding on the yeast surface?
13. How do you ensure correct protein folding on the yeast surface?
14. Do you offer deep sequencing analysis of each selection round?
14. Do you offer deep sequencing analysis of each selection round?
14. Do you offer deep sequencing analysis of each selection round?
14. Do you offer deep sequencing analysis of each selection round?
15. Can yeast display be used for therapeutic antibody discovery?
15. Can yeast display be used for therapeutic antibody discovery?
15. Can yeast display be used for therapeutic antibody discovery?
15. Can yeast display be used for therapeutic antibody discovery?
16. What antigen formats do you accept?
16. What antigen formats do you accept?
16. What antigen formats do you accept?
16. What antigen formats do you accept?
17. How are screening conditions controlled?
17. How are screening conditions controlled?
17. How are screening conditions controlled?
17. How are screening conditions controlled?
18. What are the typical deliverables at the end of a project?
18. What are the typical deliverables at the end of a project?
18. What are the typical deliverables at the end of a project?
18. What are the typical deliverables at the end of a project?
19. Can you reformat yeast-display hits into IgG or other formats?
19. Can you reformat yeast-display hits into IgG or other formats?
19. Can you reformat yeast-display hits into IgG or other formats?
19. Can you reformat yeast-display hits into IgG or other formats?
20. What is the typical project timeline?
20. What is the typical project timeline?
20. What is the typical project timeline?
20. What is the typical project timeline?

Join Us in Advancing Biotech Solutions Together

Join Us in Advancing Biotech Solutions Together

Join Us in Advancing Biotech Solutions Together

Copyright © 2025 DuneX Biosciences. All rights reserved. | +1-(415).463.0365 | info@dunexbio.com | 25801 Industrial Blvd Suite 100, Hayward, CA 94545

Copyright © 2025 DuneX Biosciences.

All rights reserved.

+1-(415).463.0365 | info@dunexbio.com |

25801 Industrial Blvd Suite 100, Hayward, CA 94545

Copyright © 2025 DuneX Biosciences. All rights reserved. | +1-(415).463.0365 | info@dunexbio.com |

25801 Industrial Blvd Suite 100, Hayward, CA 94545